Inpharmica is involved in a project aimed at performing phase III of clinical studies on an increased number of patients, including the monitoring of undesired effects and development of documentation to register a new complex pain killer patented in the USA
Inpharmica is involved in a project aimed at performing phase III of clinical studies on an increased number of patients, including the monitoring of undesired effects and development of documentation to register a new complex pain killer patented in the USA.